OP0260-HPR PREDICTORS OF WORK PARTICIPATION IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AFTER 12 MONTHS OF T2T THERAPY INTERVENTION

Background: Rheumatoid arthritis (RA) is associated with restrictions on work participation (WP) caused mainly by periods of sick leave (absenteeism), reduced productivity at due to disease (presenteeism) and occupational disability, which account for a significant proportion indirect costs. Objectives: We investigate the predictors WP after 12 months Treat-to-Target (T2T) intervention. Methods: Data were analyzed from multi-center ERFASS study, included patients rheumatoid factor and/or APCA positive RA initiation or escalation modifying anti rheumatic drug (DMARD) therapy following T2T regimen prospectively over 01/2018 12/2019. A total 157 working age (18 65 years) in this evaluation. Socio-demographic characteristics (WPAI, self-conducted questionnaire), clinical parameters including activity (DAS28, RADAI), impact (RAID), functional capacity (FFbH), depression (PHQ-9) fatigue (VAS) logistic regression analysis detect baseline unimpaired was performed. Results: The mean 52.9 years (standard deviation (SD): 8.19) 117 (74.5%) female. 51 (32.5%) started first line DMARDs 106 (67.5%) treatment escalated. resulted decrease DAS28 4.2 (SD 1.10) 2.5 1.11; p<0.001) months, 64.3% remission (DAS28<2.6) 12.1% had low (DAS28 2.6-3.2). no impairment increased significantly presenteeism absenteeism became less prevalent, but month remained high (74.1%; graph 1). observed moderate correlation between (r Mo12 =0.446; p<0.001). Patients showed greater 3.7 1.15) 1.9 0.61) as compared (mean DAS28: 4.4 1.04) 2.7 12; Results univariate analyses revealed score major contributing factors (Table Table 1. Baseline 1 Predictors (independent variables) Univariate 2 : p-values Multivariate 3 Odds Ratios, gender 0.117 + OR: 0.412; p=0.113 0.010* OR:0.951; p=0.071 school graduation 0.150 professional degree 0.739 duration complaints 0.127 group (starters vs. escalation/ change) 0.004* DAS-28(CRP) 0.001* CRP 0.906 tender joints swollen 0.021* 0.003* 0.827; p=0.086 subjective (RADAI) <0.001* burden (RAID) (FFbH) 1.477; p=0.031* 0.876; p=0.035* time model (full part-time) 0.498 physical load 0.427 dependant variable: 0=reduced (not working/ absenteeism/ (≥2)); 1=full (working without (≥2)) according applicability chi-square test, t-test independent variables, Mann-Whitney-U test binary analysis, stepwise-backward procedure into * significance level: p<0.05 Conclusion: Despite remission, we persistent limitations WP. Impaired influence capacity. Our data underscore multifactorial causes impaired WP, should be targeted vocational rehabilitation. Disclosure Interests: Sara Eileen Meyer: None declared, Juliana Rachel Hoeper: Torsten Witte: Kirsten Hoeper Speakers bureau: She has received consultancy speaker honoraria Abbvie, Chugai, Gilead, Lilly, Novartis, Sandoz Hexal Sanofi., Dirk Meyer-Olson He Amgen, Berlin Chemie, Bristol Myers Squibb, Cellgene, Fresenius Kabi, GSK, Jansen Cilag, Medac, Merck Sharp & Dome, Mylan, Pfizer, Hexal, Sanofi UCB.